Open AccessBone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene
Author(s) -
Lina Aguirre,
Georgia Colleluori,
David Robbins,
Richard I. Dorin,
Vallabh O. Shah,
Rui Chen,
Irum Zeb Jan,
Clifford Qualls,
Dennis T. Villareal,
Reina Armamento-Villareal
Publication year - 2019
Publication title -
endocrine
Language(s) - English
Resource type - Journals
eISSN - 1559-0100
pISSN - 1355-008X
DOI - 10.1007/s12020-019-02008-6
Subject(s) - hematocrit , testosterone (patch) , medicine , bone mineral , endocrinology , lean body mass , genotype , single nucleotide polymorphism , bone density , biology , osteoporosis , gene , genetics , body weight
To evaluate the influence of single nucleotide polymorphisms (SNPs) of CYP19A1 on the response and susceptibility to side effects from testosterone therapy. This is a prospective, single-arm study of men with low-morning serum testosterone (<10.68 nmol/l) administered testosterone cypionate 200 mg intramuscularly every 2 weeks for 18 months.